Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Kulke M, Ruszniewski P, Van Cutsem E, Valle J, De Herder W,
Keywords: everolimus, pNET, pasireotide LAR,
Introduction: EVE showed a significant improvement of 6.4 mo in median progression-free survival (PFS) vs PBO (HR 0.35, 95% CI 0.27-0.45; P<0.001) in patients (pts) with pNET in RADIANT-3.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Yao J, Pavel M, Lombard-Bohas C, Van Cutsem E, Lam D,
Keywords: everolimus, pNET, OS,
Introduction: A recent phase 3 trial of SU in pancreatic NET showed an improvement in progression-free survival (PFS) and OS. However, the OS benefit was confounded by early CO from placebo (PBO) to SU treatment.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Ishak J, Valle J, Van Cutsem E, Lombard-Bohas C, Ruszniewski P,
Keywords: overall survival, crossover, sunitinib, NET, Rank-Preserving Structural Failure Time model,
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Pavel M, Peeters M, Höersch D, Van Cutsem E, Öberg K,
Keywords: mTOR, everolimus, octreotide LAR, neuroendocrine tumor,